NasdaqCM:ATRS

Stock Analysis Report

Executive Summary

Antares Pharma, Inc. focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide.


Snowflake Analysis

Reasonable growth potential with mediocre balance sheet.


Similar Companies

Share Price & News

How has Antares Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ATRS's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-5.0%

ATRS

-1.7%

US Medical Equipment

-4.1%

US Market


1 Year Return

-26.9%

ATRS

-8.2%

US Medical Equipment

-14.9%

US Market

Return vs Industry: ATRS underperformed the US Medical Equipment industry which returned -7.8% over the past year.

Return vs Market: ATRS underperformed the US Market which returned -13.6% over the past year.


Shareholder returns

ATRSIndustryMarket
7 Day-5.0%-1.7%-4.1%
30 Day-32.8%-14.1%-19.1%
90 Day-50.9%-19.2%-23.4%
1 Year-26.9%-26.9%-7.4%-8.2%-13.2%-14.9%
3 Year-29.6%-29.6%40.6%36.8%10.7%3.5%
5 Year-26.4%-26.4%69.3%51.7%28.5%14.5%

Price Volatility Vs. Market

How volatile is Antares Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Antares Pharma undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ATRS ($2.09) is trading below our estimate of fair value ($10.47)

Significantly Below Fair Value: ATRS is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ATRS is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: ATRS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ATRS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ATRS is overvalued based on its PB Ratio (6.3x) compared to the US Medical Equipment industry average (2.9x).


Next Steps

Future Growth

How is Antares Pharma forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

40.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ATRS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).

Earnings vs Market: ATRS is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ATRS's is expected to become profitable in the next 3 years.

Revenue vs Market: ATRS's revenue (16.7% per year) is forecast to grow faster than the US market (7.2% per year).

High Growth Revenue: ATRS's revenue (16.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ATRS's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Antares Pharma performed over the past 5 years?

31.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ATRS is currently unprofitable.

Growing Profit Margin: ATRS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ATRS is unprofitable, but has reduced losses over the past 5 years at a rate of 31.5% per year.

Accelerating Growth: Unable to compare ATRS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ATRS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1%).


Return on Equity

High ROE: ATRS has a negative Return on Equity (-3.72%), as it is currently unprofitable.


Next Steps

Financial Health

How is Antares Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: ATRS's short term assets ($108.4M) exceed its short term liabilities ($32.4M).

Long Term Liabilities: ATRS's short term assets ($108.4M) exceed its long term liabilities ($45.8M).


Debt to Equity History and Analysis

Debt Level: ATRS's debt to equity ratio (74.1%) is considered high.

Reducing Debt: Insufficient data to determine if ATRS's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: ATRS has a high level of physical assets or inventory.

Debt Coverage by Assets: ATRS's debt is covered by short term assets (assets are 2.7x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ATRS has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ATRS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Antares Pharma's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ATRS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ATRS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ATRS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ATRS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ATRS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.6yrs

Average management tenure


CEO

Bob Apple (53yo)

4.25s

Tenure

US$3,452,880

Compensation

Mr. Robert F. Apple, also known as Bob, has been the Chief Executive Officer and President of Antares Pharma Inc. since January 25, 2016. Mr. Apple served as Chief Operating Officer of Antares Pharma Inc.  ...


CEO Compensation Analysis

Compensation vs Market: Bob's total compensation ($USD3.45M) is above average for companies of similar size in the US market ($USD2.20M).

Compensation vs Earnings: Bob's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Robert Apple
CEO, President & Director4.25yrsUS$3.45m1.22% $4.2m
Fred Powell
Executive VP & CFO3.5yrsUS$1.33m0.21% $710.0k
Peter Graham
Executive VP of Human Resources4.75yrsUS$1.35m0.14% $501.3k
James Tursi
Executive VP1.67yrsUS$745.48kno data
Patrick Madsen
Senior Vice President of Operationsno datano datano data
Keith Muckenhirn
Principal Accounting Officer3.58yrsUS$361.46kno data
Edward Tykot
Senior Vice President of Corporate Development0.33yrno datano data
Peter Sadowski
Senior Vice President of Technology Portfolio & Intellectual Propertyno dataUS$467.99kno data
Steven Knapp
Senior Vice President of Regulatory Affairs & Quality Assurance4.08yrsno datano data
Edward Kessig
Senior Vice President of Commercialno datano datano data

3.6yrs

Average Tenure

55yo

Average Age

Experienced Management: ATRS's management team is considered experienced (3.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Robert Apple
CEO, President & Director4.25yrsUS$3.45m1.22% $4.2m
Robert Roche
Independent Director6.75yrsUS$167.00k0.053% $184.3k
Leonard Jacob
Independent Chairman11.5yrsUS$327.50k0.11% $365.9k
Marvin Samson
Independent Director6.92yrsUS$165.00k0.017% $58.1k
Thomas Garrity
Independent Director16.5yrsUS$182.82k0.10% $355.7k
Anton Gueth
Independent Director16.5yrsUS$186.82k0.18% $632.8k
Peter Greenleaf
Independent Director1.33yrsUS$35.32kno data
Karen Smith
Independent Director1.08yrsno datano data

6.8yrs

Average Tenure

62.5yo

Average Age

Experienced Board: ATRS's board of directors are considered experienced (6.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.3%.


Top Shareholders

Company Information

Antares Pharma, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Antares Pharma, Inc.
  • Ticker: ATRS
  • Exchange: NasdaqCM
  • Founded: 1978
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$346.021m
  • Shares outstanding: 165.56m
  • Website: https://www.antarespharma.com

Number of Employees


Location

  • Antares Pharma, Inc.
  • 100 Princeton South
  • Suite 300
  • Ewing
  • New Jersey
  • 8628
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ATRSNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDFeb 2001
MJCDB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2001
MJCBRSE (Berne Stock Exchange)YesCommon StockCHCHFFeb 2001

Biography

Antares Pharma, Inc. focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company’s injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Its injection products also comprise Epinephrine Injection USP for treating Anaphylaxis; Makena auto injectors to reduce the risk of preterm birth in women pregnant with a single baby; ZOMAJET and Twin-Jector EZ II Needle-free Injectors to administer human growth hormone for patients with growth retardation. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; and QuickShot auto injectors. It has strategic alliances with Teva Pharmaceutical Industries, Ltd., AMAG Pharmaceuticals, Inc., and Pfizer Inc. The company was founded in 1978 and is headquartered in Ewing, New Jersey. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/02 02:22
End of Day Share Price2020/04/01 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.